The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

Abstract

Purpose: The receptor tyrosine kinase c-Met plays an important role in tumorigenesis and is a novel target for anticancer treatment. This phase I, first-in-human trial, explored safety, pharmacokinetics, pharmacodynamics, and initial antitumor activity of JNJ-38877605, a potent and selective c-Met inhibitor.Experimental Design: We performed a phase I dose-escalation study according to the standard 3þ3 design.Results: Even at subtherapeutic doses, mild though recurrent renal toxicity was observed in virtually all patients. Renal toxicity had not been observed in preclinical studies in rats and dogs. Additional preclinical studies pointed toward the rabbit as a suitable toxicology model, as the formation of the M10 metabolite of JNJ-38877605 specifically occurred in rabbits and humans. Additional toxicology studies in rabbits clearly demonstrated that JNJ-38877605 induced species-specific renal toxicity.Histopathological evaluation in rabbits revealed renal crystal formation with degenerative and inflammatory changes. Identification of the components of these renal crystals revealed M1/3 and M5/6 metabolites. Accordingly, it was found that humans and rabbits showed significantly increased systemic exposure to these metabolites relative to other species. These main culprit insoluble metabolites were generated by aldehyde oxidase activity. Alternative dosing schedules of JNJ-3877605 and concomitant probenecid administration in rabbits failed to prevent renal toxicity at dose levels that could be pharmacologically active.Conclusions: Combined clinical and correlative preclinical studies suggest that renal toxicity of JNJ-38877605 is caused by the formation of species-specific insoluble metabolites. These observations preclude further clinical development of JNJ-38877605.

Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress

“…BCR-ABL promotes Mcl-1 expression mediated by the RAS/RAF/MEK/ERK and STAT5 pathways [15], and MEK/ERK positively regulates Mcl-1 expression [43, 44]. Consistent with this, we demonstrated that BCR-ABL upregulated MEK/ERK to promote Mcl-1 expression in BCR-ABL+ ALL cells, and that these pathways play a crucial role in the survival in BCR-ABL+ ALL via Mcl-1.…”

Evaluating the Disposition of a Mixed Aldehyde Oxidase/Cytochrome P450 Substrate in Rats with Attenuated P450 Activity

“…1.20 6 1.10 17.1 6 11.9 14 n/a n/a n/a n/a *P , 0.05; **P , 0.01. Lolkema et al, 2015). Additionally, the primary circulating metabolite of idealisib, GS-563117, is a mechanism-based inhibitor of P450 3A, which is not the case for the parent drug.…”

Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics

“…5) (Infante et al, 2013). Both of these c-Met inhibitors are substrates of AO and are converted to their respective quinolone metabolites via oxidation of the carbon atom adjacent to the nitrogen atom in the quinoline ring (Diamond et al, 2010;Lolkema et al, 2015). Poor solubility of the quinolone metabolite leads to its crystallization in the kidney, subsequently resulting in the observed renal toxicity in some species and humans.…”